Advertisement

Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations

  • Amanda B. Hesterberg
    Affiliations
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
    Search for articles by this author
  • Jennifer B. Gordetsky
    Affiliations
    Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN

    Department of Urology, Vanderbilt University Medical Center, Nashville, TN
    Search for articles by this author
  • Paula J. Hurley
    Correspondence
    Address correspondence to: Paula J. Hurley, Vanderbilt University Medical Center 2220 Pierce Avenue, 648 Preston Research Building Nashville, TN 37232.
    Affiliations
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

    Department of Urology, Vanderbilt University Medical Center, Nashville, TN

    Vanderbilt-Ingram Cancer Center, Nashville, TN
    Search for articles by this author
      Intraductal cribriform (IDC) and invasive cribriform morphologies are associated with worse prostate cancer outcomes. Limited retrospective studies have associated IDC and cribriform morphology with germline mutations in DNA repair genes, particularly BRCA2. These findings, which prompted the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer and Genetic/Familial High- Risk Assessment to consider germline testing for individuals with IDC/cribriform histology, have been questioned in a recent prospective study. A deepened understanding of the molecular mechanisms driving disease aggressiveness in cribriform morphology is critical to provide more clarity in clinical decision making. This review summarizes the current understanding of IDC and cribriform prostate cancer, with an emphasis on clinical outcomes and molecular alterations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chen N
        • Zhou Q.
        The evolving Gleason grading system.
        Chin J Cancer Res. 2016; 28: 58-64
        • Gleason DF.
        Classification of prostatic carcinomas.
        Cancer Chemother Rep. 1966; 50: 125-128
        • Epstein JI.
        Prostate cancer grading: a decade after the 2005 modified system.
        Mod Pathol. 2018; 31: S47-S63
        • Wright JL
        • Salinas CA
        • Lin DW
        • et al.
        Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort.
        J Urol. 2009; 182: 2702-2707
        • Kweldam CF
        • van der Kwast T
        • van Leenders GJ.
        On cribriform prostate cancer.
        Transl Androl Urol. 2018; 7: 145-154
        • Trudel D
        • Downes MR
        • Sykes J
        • Kron KJ
        • Trachtenberg J
        • van der Kwast TH.
        Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort.
        Eur J Cancer. 2014; 50: 1610-1616
        • Kweldam CF
        • Wildhagen MF
        • Steyerberg EW
        • Bangma CH
        • van der Kwast TH
        • van Leenders GJ.
        Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer.
        Mod Pathol. 2015; 28: 457-464
        • Kir G
        • Sarbay BC
        • Gumus E
        • Topal CS.
        The association of the cribriform pattern with outcome for prostatic adenocarcinomas.
        Pathol Res Pract. 2014; 210: 640-644
        • Dong F
        • Yang P
        • Wang C
        • et al.
        Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma.
        Am J Surg Pathol. 2013; 37: 1855-1861
        • Elfandy H
        • Armenia J
        • Pederzoli F
        • et al.
        Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.
        Mol Cancer Res. 2019; 17: 446-456
        • Branca G
        • Ieni A
        • Barresi V
        • Tuccari G
        • Caruso RA.
        An Updated Review of Cribriform Carcinomas with Emphasis on Histopathological Diagnosis and Prognostic Significance.
        Oncol Rev. 2017; 11: 317
        • Chua MLK
        • Lo W
        • Pintilie M
        • et al.
        A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
        Eur Urol. 2017; 72: 665-674
        • Tom MC
        • Nguyen JK
        • Luciano R
        • et al.
        Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
        J Urol. 2019; 202: 710-716
        • Epstein JI
        • Hirsch MS.
        A Comparison of Genitourinary Pathology Society (GUPS) and International Society of Urological Pathology (ISUP) Prostate Cancer Grading Guidelines.
        Am J Surg Pathol. 2021; : 1-14
        • Van der Kwast T
        • Al Daoud N
        • Collette L
        • et al.
        Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy.
        Eur J Cancer. 2012; 48: 1318-1325
        • Bottcher R
        • Kweldam CF
        • Livingstone J
        • et al.
        Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
        BMC Cancer. 2018; 18: 8
        • Taylor AS
        • Morgan TM
        • Wallington DG
        • Chinnaiyan AM
        • Spratt DE
        • Mehra R.
        Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
        Prostate. 2020; 80: 146-152
        • van Leenders G
        • Kweldam CF
        • Hollemans E
        • et al.
        Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
        Eur Urol. 2020; 77: 191-198
        • van Leenders G
        • van der Kwast TH
        • Grignon DJ
        • et al.
        The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.
        Am J Surg Pathol. 2020; 44: e87-e99
        • Epstein JI
        • Amin MB
        • Fine SW
        • et al.
        The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
        Arch Pathol Lab Med. 2020; : 1-14
        • Haffner MC
        • Salles DC
        • Gao G
        • Epstein JI.
        Gleason pattern 4 with cribriform morphology on biopsy is associated with adverse clinicopathological findings in a prospective radical prostatectomy cohort.
        Hum Pathol. 2020; 98: 74-80
        • Kweldam CF
        • Kummerlin IP
        • Nieboer D
        • et al.
        Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.
        Mod Pathol. 2017; 30: 1126-1132
        • Wang X
        • Qi M
        • Zhang J
        • et al.
        Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
        Prostate. 2019; 79: 709-719
        • Downes MR
        • Xu B
        • van der Kwast TH.
        Gleason grade patterns in nodal metastasis and corresponding prostatectomy specimens: impact on patient outcome.
        Histopathology. 2019; 75: 715-722
        • Hollemans E
        • Verhoef EI
        • Bangma CH
        • et al.
        Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients.
        Mod Pathol. 2021; 34: 184-193
        • Kweldam CF
        • Kummerlin IP
        • Nieboer D
        • et al.
        Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.
        Mod Pathol. 2016; 29: 630-636
        • Iczkowski KA
        • Torkko KC
        • Kotnis GR
        • et al.
        Digital quantification of five high- grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.
        Am J Clin Pathol. 2011; 136: 98-107
        • McKenney JK
        • Wei W
        • Hawley S
        • et al.
        Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.
        Am J Surg Pathol. 2016; 40: 1439-1456
        • Keefe DT
        • Schieda N
        • El Hallani S
        • et al.
        Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
        Virchows Arch. 2015; 467: 437-442
        • Hollemans E
        • Verhoef EI
        • Bangma CH
        • et al.
        Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis.
        Mod Pathol. 2019; 32: 139-146
        • Greenland NY
        • Zhang L
        • Cowan JE
        • Carroll PR
        • Stohr BA
        • Simko JP.
        Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer.
        J Urol. 2019; 202: 90-95
        • Ambrosini P
        • Hollemans E
        • Kweldam CF
        • Leenders G
        • Stallinga S
        • Vos F.
        Automated detection of cribriform growth patterns in prostate histology images.
        Sci Rep. 2020; 10: 14904
        • Hollemans E
        • Verhoef EI
        • Bangma CH
        • et al.
        Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens.
        Histopathology. 2019; 75: 338-345
        • Ericson KJ
        • Wu SS
        • Lundy SD
        • Thomas LJ
        • Klein EA
        • McKenney JK.
        Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance.
        J Urol. 2020; 203: 311-319
        • Masoomian M
        • Downes MR
        • Sweet J
        • et al.
        Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set.
        Histopathology. 2019; 74: 474-482
        • Truong M
        • Hollenberg G
        • Weinberg E
        • Messing EM
        • Miyamoto H
        • Frye TP.
        Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology.
        J Urol. 2017; 198: 316-321
        • Truong M
        • Feng C
        • Hollenberg G
        • et al.
        A Comprehensive Analysis of Cribriform Morphology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Correlated with Radical Prostatectomy Specimens.
        J Urol. 2018; 199: 106-113
        • Houlahan KE
        • Salmasi A
        • Sadun TY
        • et al.
        Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.
        Eur Urol. 2019; 76: 18-23
        • van Houdt PJ
        • Ghobadi G
        • Schoots IG
        • et al.
        Histopathological Features of MRI- Invisible Regions of Prostate Cancer Lesions.
        J Magn Reson Imaging. 2020; 51: 1235-1246
        • Prendeville S
        • Gertner M
        • Maganti M
        • et al.
        Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
        J Urol. 2018; 200: 104-113
        • Tonttila PP
        • Ahtikoski A
        • Kuisma M
        • Paakko E
        • Hirvikoski P
        • Vaarala MH.
        Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer.
        BJU Int. 2019; 124: 992-998
        • Naito H
        • Kato T
        • Ishikawa R
        • et al.
        The Impact of Histopathological Features of Prostate Cancerous Lesions on Multiparametric Magnetic Resonance Imaging Findings using PI-RADS Version 2.
        Urology. 2021; 149: 174-180
        • Gao J
        • Zhang C
        • Zhang Q
        • et al.
        Diagnostic performance of (68)Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections.
        Eur J Nucl Med Mol Imaging. 2019; 46: 1531-1541
        • Gao J
        • Zhang Q
        • Fu Y
        • et al.
        Combined clinical characteristics and multiparametric MRI parameters for prediction of cribriform morphology in intermediate-risk prostate cancer patients.
        Urol Oncol. 2020; 38: 216-224
        • Risbridger GP
        • Taylor RA
        • Clouston D
        • et al.
        Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
        Eur Urol. 2015; 67: 496-503
        • Taylor RA
        • Fraser M
        • Livingstone J
        • et al.
        Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
        Nat Commun. 2017; 8: 13671
        • Schweizer MT
        • Antonarakis ES
        • Bismar TA
        • et al.
        Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.
        JCO Precis Oncol. 2019; 3: 1-14
        • Castro E
        • Goh C
        • Olmos D
        • et al.
        Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
        J Clin Oncol. 2013; 31: 1748-1757
        • Na R
        • Zheng SL
        • Han M
        • et al.
        Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
        Eur Urol. 2017; 71: 740-747
      1. National Comprehensive Cancer Network - Prostate NCCN-. 2.2021.

      2. National Comprehensive Cancer Network - Genetic/Familial High-Risk Assessment: Breast O, and Pancreatic 2.
        2021
        • Lozano R
        • Salles DC
        • Sandhu S
        • et al.
        Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
        European Journal of Cancer. 2021; 147: 74-83
        • Friedlander TW
        • Roy R
        • Tomlins SA
        • et al.
        Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.
        Cancer Res. 2012; 72: 616-625
        • Torquato S
        • Pallavajjala A
        • Goldstein A
        • et al.
        Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.
        JCO Precis Oncol. 2019; 3: 1-14
        • Abida W
        • Armenia J
        • Gopalan A
        • et al.
        Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
        JCO Precis Oncol. 2017; 2017: 1-14
        • Annala M
        • Vandekerkhove G
        • Khalaf D
        • et al.
        Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
        Cancer Discov. 2018; 8: 444-457
        • Grasso CS
        • Wu YM
        • Robinson DR
        • et al.
        The mutational landscape of lethal castration-resistant prostate cancer.
        Nature. 2012; 487: 239-243
        • Mosquera JM
        • Perner S
        • Demichelis F
        • et al.
        Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
        J Pathol. 2007; 212: 91-101
        • Olkhov-Mitsel E
        • Siadat F
        • Kron K
        • et al.
        Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors.
        Oncol Lett. 2017; 14: 390-396
        • Prensner JR
        • Zhao S
        • Erho N
        • et al.
        RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
        Lancet Oncol. 2014; 15: 1469-1480
        • Mukai S
        • Yorita K
        • Yamasaki K
        • et al.
        Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis.
        Hum Cell. 2015; 28: 133-142
        • Cannistraci A
        • Federici G
        • Addario A
        • et al.
        C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition.
        Oncogene. 2017; 36: 3718-3728
        • Xiao GQ
        • Nguyen E
        • Unger PD
        • Sherrod AE.
        Comparative expression of immunohistochemical biomarkers in cribriform and pattern 4 non-cribriform prostatic adenocarcinoma.
        Exp Mol Pathol. 2020; 114104400
        • Fu L
        • Hwang M
        • Adeniran AJ
        • Humphrey PA.
        Proliferation index of different Gleason pattern 4 histomorphologies and associated pattern 3 adenocarcinoma of the prostate.
        Hum Pathol. 2017; 70: 1-5
        • Ronen S
        • Abbott DW
        • Kravtsov O
        • et al.
        PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.
        Hum Pathol. 2017; 65: 85-91
        • Shah RB
        • Shore KT
        • Yoon J
        • Mendrinos S
        • McKenney JK
        • Tian W.
        PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
        Prostate. 2019; 79: 1267-1273
        • Chen HH
        • Fan P
        • Chang SW
        • Tsao YP
        • Huang HP
        • Chen SL.
        NRIP/DCAF6 stabilizes the androgen receptor protein by displacing DDB2 from the CUL4A- DDB1 E3 ligase complex in prostate cancer.
        Oncotarget. 2017; 8: 21501-21515
        • Connell B
        • Kopach P
        • Ren W
        • et al.
        Aberrant integrin alphav and alpha5 expression in prostate adenocarcinomas and bone-metastases is consistent with a bone-colonizing phenotype.
        Transl Androl Urol. 2020; 9: 1630-1638
        • Verhoef EI
        • van Cappellen WA
        • Slotman JA
        • et al.
        Three-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patterns.
        Mod Pathol. 2019; 32: 1032-1041
        • Hesterberg AB
        • Rios BL
        • Wolf EM
        • et al.
        A distinct repertoire of cancer- associated fibroblasts is enriched in cribriform prostate cancer.
        J Pathol Clin Res. 2021; : 1-14